Defence Therapeutics Inc.
DTC
Rang in Aktien
#29535
Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a... Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerstone of its approach is the exclusive ACCUM™ technology, engineered to precisely and safely transport vaccine antigens or antibody-drug conjugates (ADCs) directly to their intended cellular targets. The company's development efforts span several key areas: novel dendritic cell vaccines for various cancers, protein-based vaccines addressing COVID-19 and other infectious ailments, and specialized antibody-drug conjugate products aimed at different cancer types. Defence Therapeutics Inc. adopted its current name in March 2020, having previously operated as Accum Therapeutics Inc.
Aktienkurs
$0.25964327
Marktkapitalisierung
$19.68M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-55.64%
Land
CA
Handel Defence Therapeutics Inc. (DTC)
Kategorie
Healthcare
Kursverlauf für Defence Therapeutics Inc. (DTC)
Höchster Schlusskurs: $0.27 am 2026-10-01
Niedrigster Schlusskurs: $2.50 am 2021-05-01
Niedrigster Schlusskurs: $2.50 am 2021-05-01
Kursverlauf der Aktie von Defence Therapeutics Inc. von 2021 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | -27.55% |
| 2025 | 58.71% |
| 2024 | -79.59% |
| 2023 | -28.12% |
| 2022 | -37.44% |
| 2021 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
